Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Christina Falcon"'
Autor:
Ezra Y. Rosen, Helen H. Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D. Friedman, Ino de Bruijn, Onur Sumer, Craig M. Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srusthi Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J. Brandhuber, James Fagin, Eric J. Sherman, Natasha Rekhtman, Michael F. Berger, Maurizio Scaltriti, David M. Hyman, Barry S. Taylor, Alexander Drilon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
The results of the phase 1/2 LIBRETTO-001 clinical trial has recently established the efficacy of the RET inhibitor selpercatinib in RET-driven cancers. Here, the authors characterize the molecular determinants of response and resistance in 72 LIBRET
Externí odkaz:
https://doaj.org/article/c9aadc1f6bbc44acba731c2a7dcb7aef
Autor:
Ezra Y. Rosen, Helen H. Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D. Friedman, Ino de Bruijn, Onur Sumer, Craig M. Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srushti Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J. Brandhuber, James Fagin, Eric J. Sherman, Natasha Rekhtman, Michael F. Berger, Maurizio Scaltriti, David M. Hyman, Barry S. Taylor, Alexander Drilon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/5da51ab03db947f7a3ffd0a6118bb43a
Autor:
Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz, Andrew J. Piper-Valillo, Zofia Piotrowska, Christina Falcon, Helena A. Yu, Charu Aggarwal, Dylan Scholes, Tejas Patil, Christina Nguyen, Manali Phadke, Fang-Yong Li, Joel Neal, Mark A. Lemmon, Zenta Walther, Katerina Politi, Sarah B. Goldberg
Publikováno v:
Clinical Cancer Research. 29:2123-2130
Purpose: The uncommon EGFR exon 19 deletion (ex19del), L747_A750>P, demonstrates reduced sensitivity to osimertinib compared with the common ex19del, E746_A750del in preclinical models. The clinical efficacy of osimertinib in patients with non–smal
Autor:
Sarah B. Goldberg, Katerina Politi, Zenta Walther, Mark A. Lemmon, Joel Neal, Fang-Yong Li, Manali Phadke, Christina Nguyen, Tejas Patil, Dylan Scholes, Charu Aggarwal, Helena A. Yu, Christina Falcon, Zofia Piotrowska, Andrew J. Piper-Valillo, Anna Wurtz, Iris K. van Alderwerelt van Rosenburgh, Paul Stockhammer, Jacqueline H. Starrett, Jacqueline V. Aredo, Michael J. Grant
Supplementary Figure S3. Progression Free Survival for patients with tumors harboring select exon 19 deletions treated with second or later line osimertinib (T790M+). The point estimate for median progression free survival associated with each mutati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6212fa6eedce5e7e3c197a0dc1bfdad4
https://doi.org/10.1158/1078-0432.22651608
https://doi.org/10.1158/1078-0432.22651608
Autor:
Sarah B. Goldberg, Katerina Politi, Zenta Walther, Mark A. Lemmon, Joel Neal, Fang-Yong Li, Manali Phadke, Christina Nguyen, Tejas Patil, Dylan Scholes, Charu Aggarwal, Helena A. Yu, Christina Falcon, Zofia Piotrowska, Andrew J. Piper-Valillo, Anna Wurtz, Iris K. van Alderwerelt van Rosenburgh, Paul Stockhammer, Jacqueline H. Starrett, Jacqueline V. Aredo, Michael J. Grant
Purpose:The uncommon EGFR exon 19 deletion (ex19del), L747_A750>P, demonstrates reduced sensitivity to osimertinib compared with the common ex19del, E746_A750del in preclinical models. The clinical efficacy of osimertinib in patients with non–small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4455ab4c1799ba13f63c8913712becae
https://doi.org/10.1158/1078-0432.c.6604893.v1
https://doi.org/10.1158/1078-0432.c.6604893.v1
Autor:
Sarah B. Goldberg, Katerina Politi, Zenta Walther, Mark A. Lemmon, Joel Neal, Fang-Yong Li, Manali Phadke, Christina Nguyen, Tejas Patil, Dylan Scholes, Charu Aggarwal, Helena A. Yu, Christina Falcon, Zofia Piotrowska, Andrew J. Piper-Valillo, Anna Wurtz, Iris K. van Alderwerelt van Rosenburgh, Paul Stockhammer, Jacqueline H. Starrett, Jacqueline V. Aredo, Michael J. Grant
Supplementary Table S1. Descriptive analysis of patient characteristics and outcomes for those with tumors harboring uncommon exon 19 deletions treated with osimertinib. Each variant represented ≤2.5% of the study cohort. Patients with + for “Smo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d11c6eb873c8463a1638764ea648a73
https://doi.org/10.1158/1078-0432.22651605.v1
https://doi.org/10.1158/1078-0432.22651605.v1
Autor:
Natasha Rekhtman, Alexander Drilon, Marc Ladanyi, William D. Travis, Maria E. Arcila, Alison M. Schram, Bob T. Li, Laetitia Borsu, Khedoudja Nafa, Ryma Benayed, Joshua K. Sabari, Sarah Teed, Valerie W. Rusch, Prasad S. Adusumilli, Kyuichi Kadota, Patrice Desmeules, Joseph Montecalvo, Sharon Amir, Helen H. Won, Vasilisa A. Rudneva, Fanli Meng, Brian R. Houck-Loomis, David Brown, Christina Falcon, Michael Offin, Jason C. Chang
Supplemental Methods 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c3f8118ca794b752039fbf3a74ead09
https://doi.org/10.1158/1078-0432.22480620.v1
https://doi.org/10.1158/1078-0432.22480620.v1
Autor:
Natasha Rekhtman, Alexander Drilon, Marc Ladanyi, William D. Travis, Maria E. Arcila, Alison M. Schram, Bob T. Li, Laetitia Borsu, Khedoudja Nafa, Ryma Benayed, Joshua K. Sabari, Sarah Teed, Valerie W. Rusch, Prasad S. Adusumilli, Kyuichi Kadota, Patrice Desmeules, Joseph Montecalvo, Sharon Amir, Helen H. Won, Vasilisa A. Rudneva, Fanli Meng, Brian R. Houck-Loomis, David Brown, Christina Falcon, Michael Offin, Jason C. Chang
Supplemental Figure 1. Consort diagram summarizing the molecular workflow of cases.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f905210b512906f9de773d585eddb603
https://doi.org/10.1158/1078-0432.22480635
https://doi.org/10.1158/1078-0432.22480635
Autor:
Natasha Rekhtman, Alexander Drilon, Marc Ladanyi, William D. Travis, Maria E. Arcila, Alison M. Schram, Bob T. Li, Laetitia Borsu, Khedoudja Nafa, Ryma Benayed, Joshua K. Sabari, Sarah Teed, Valerie W. Rusch, Prasad S. Adusumilli, Kyuichi Kadota, Patrice Desmeules, Joseph Montecalvo, Sharon Amir, Helen H. Won, Vasilisa A. Rudneva, Fanli Meng, Brian R. Houck-Loomis, David Brown, Christina Falcon, Michael Offin, Jason C. Chang
Supplemental Figure 3. Comparison of overall and recurrence-free survival in TP53-wild type and TP53-mutant IMAs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01c9a42c08d2366fbb960cdbdb3c939f
https://doi.org/10.1158/1078-0432.22480629.v1
https://doi.org/10.1158/1078-0432.22480629.v1
Autor:
Natasha Rekhtman, Alexander Drilon, Marc Ladanyi, William D. Travis, Maria E. Arcila, Alison M. Schram, Bob T. Li, Laetitia Borsu, Khedoudja Nafa, Ryma Benayed, Joshua K. Sabari, Sarah Teed, Valerie W. Rusch, Prasad S. Adusumilli, Kyuichi Kadota, Patrice Desmeules, Joseph Montecalvo, Sharon Amir, Helen H. Won, Vasilisa A. Rudneva, Fanli Meng, Brian R. Houck-Loomis, David Brown, Christina Falcon, Michael Offin, Jason C. Chang
Supplemental Methods 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79b6c8a229a7ebc2659a4facae4c05da
https://doi.org/10.1158/1078-0432.22480623
https://doi.org/10.1158/1078-0432.22480623